Global Newborn Screening Market Report and Forecast 2023-2031

Global Newborn Screening Market Report and Forecast 2023-2031

Global Newborn Screening Market Outlook

The global newborn screening market size attained a value of USD 1.10 billion in 2022. The market is likely to grow at a CAGR of 9.30% during the forecast period of 2023-2031, likely to attain a value of USD 2.46 billion by 2031.

Newborn Screening Market: Introduction

Newborn screening is a comprehensive public health program aimed at the early identification of congenital disorders in newborns. These screenings involve simple tests performed within the first few days of a baby's life to detect specific conditions that may lead to severe health issues or even death if not addressed promptly. Early detection and intervention enable healthcare providers to initiate appropriate treatment and management plans to improve outcomes and quality of life for affected infants.

Applications of Newborn Screening:

Newborn screening typically tests for a range of genetic, metabolic, and endocrine disorders, as well as certain blood and hearing conditions. The specific conditions tested vary by country and region, but some commonly screened disorders include:

• Phenylketonuria (PKU): A metabolic disorder that results in the body's inability to break down the amino acid phenylalanine, leading to intellectual disabilities and other complications if left untreated.
• Cystic Fibrosis (CF): A genetic disorder affecting the respiratory and digestive systems, causing thick mucus build-up in the lungs and pancreas.
• Sickle Cell Disease (SCD): A group of inherited red blood cell disorders characterized by misshapen, "sickle-shaped" cells that can cause severe pain, organ damage, and other complications.
• Congenital Hypothyroidism (CH): A condition in which the thyroid gland does not produce enough thyroid hormone, leading to developmental delays and growth problems if left untreated.
• Hearing loss: Early detection of hearing loss allows for early intervention, which can significantly improve language and communication skills in affected children.

Benefits of Newborn screening include the following:

Newborn screening offers numerous benefits, including:

• Early detection: Identifying disorders early allows for prompt treatment and management, which can help prevent or minimize severe health issues and improve overall outcomes.
• Improved quality of life: Early intervention can lead to better management of symptoms, allowing affected children to lead healthier, more fulfilling lives.
• Cost-effectiveness: By detecting and treating disorders early, newborn screening can reduce long-term healthcare costs associated with managing complications and disabilities that may arise if left undiagnosed and untreated.
• Reduction in infant mortality: Early detection and treatment can reduce the risk of death from certain disorders, improving overall infant survival rates.
• Family support and planning: Identification of genetic disorders in a newborn can help inform family planning decisions, allowing parents to make informed choices about future pregnancies.

In summary, Newborn screening is a vital public health initiative that offers numerous benefits to infants, families, and society as a whole. Early detection and intervention for a range of disorders can improve the quality of life and long-term outcomes for affected children, reducing healthcare costs and promoting overall health and well-being.

Newborn Screening Market Segmentations

The market can be categorised into product type, technology, test type, disease type, end user, and major region.

Market Breakup by Product Type

• Instruments
• Reagents and Assay Kits

Market Breakup by Technology

• Tandem Mass Spectrometry
• Pulse Oximetry
• Enzyme Based Assays
• DNA Assays
• Electrophoresis
• Others

Market Breakup by Test Type

• Dry Blood Spot Test
• Critical Congenital Heart Disease (CCHD)
• Hearing Screen
• Others

Market Breakup by Diseases Type

• Critical Congenital Heart Diseases
• Newborn Hearing Loss
• Sickle Cell Disease
• Phenylketonuria (PKU)
• Cystic Fibrosis (CF)
• Maple Syrup Urine Disease
• Others

Market Breakup by End User

• Clinical Laboratory
• Hospitals
• Diagnostic Centre’s
• Others

Market Breakup by Region

• North America
• United States of America
• Canada
• Europe
• United Kingdom
• Germany
• France
• Italy
• Others
• Asia Pacific
• China
• Japan
• India
• ASEAN
• Australia
• Others
• Latin America
• Brazil
• Argentina
• Mexico
• Others
• Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Newborn Screening Market Scenario

The newborn screening market has been experiencing significant growth in recent years due to several factors, including advancements in technology, increasing awareness about the benefits of early detection, and government initiatives to support the widespread implementation of screening programs.

Technological advancements have played a crucial role in the expansion of the newborn screening market. The introduction of advanced screening techniques, such as tandem mass spectrometry and next-generation sequencing, has increased the accuracy, speed, and range of conditions that can be detected. These technological innovations have made it possible to screen for a larger number of disorders, including rare conditions, with a high degree of precision.

Raising awareness about the importance of newborn screening has also contributed to market growth. Educational campaigns and initiatives by healthcare organizations, non-profit organizations, and governments have emphasized the benefits of early detection and intervention for various disorders. This increased awareness has led to a higher demand for newborn screening services, as parents and healthcare providers recognize the value of these tests in promoting infant health and well-being.

Government initiatives have played a key role in expanding the newborn screening market. Many countries have implemented mandatory newborn screening programs, ensuring that all newborns receive the necessary tests as a standard part of their postnatal care. These programs have increased the demand for screening services and have made newborn screening more accessible and affordable for all families.

Despite the overall growth in the newborn screening market, there are still challenges to address. One of the main challenges is the disparity in the availability and accessibility of newborn screening services between high-income and low-income countries. In resource-limited settings, inadequate healthcare infrastructure, lack of trained professionals, and financial constraints can hinder the implementation of comprehensive newborn screening programs. Efforts are being made to bridge this gap through global partnerships and collaborations, aiming to improve access to screening services for all newborns, regardless of their location or socioeconomic background.

Overall, the newborn screening market is expected to continue its growth trajectory in the coming years, driven by ongoing technological advancements, increased awareness, and government support. However, addressing the challenges faced by low-income countries will be crucial to ensuring equitable access to these life-saving services for all newborns worldwide.

Key Players in the Global Newborn Screening Market

The report gives an in-depth analysis of the key players involved in the newborn screening market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• PerkinElmer Inc.
• Demant A/S
• Natus Medical Incorporated
• Bio-Rad Laboratories
• Luminex Corporation
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Bruker
• Danaher
• Medtronic
• Chromsystems Instruments & Chemicals GmbH
• Trivitron Healthcare
• Baebies Inc

*Please Note:* The report will be completed in 7 business days after order confirmation